SuperGen, Inc. To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference

DUBLIN, Calif., Feb. 7 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that James S. Manuso, Ph.D., President and Chief Executive Officer is scheduled to present at The 8th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, on Tuesday, February 14, 2006 at 3:00 p.m. ET. Dr. Manuso will provide a brief corporate overview and discuss the Company's recent progress, including the Company's recently announced agreement to acquire Montigen Pharmaceuticals.

A live webcast of Dr. Manuso's presentation on February 14, 2006 will be available on the Investor Relations section of the Company's website at http://www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's product portfolio includes: Nipent(R) (pentostatin for injection); Mitomycin (generic brand of Mutamycin(R)); and SurfaceSafe(R) cleaner.

For more information about SuperGen, please visit http://www.supergen.com. Contacts: Timothy L. Enns Sharon Weinstein SuperGen, Inc. Noonan Russo Tel: (925) 560-0100 x111 Tel: (212) 845-4271 E-mail: tenns@supergen.com E-mail: sharon.weinstein@eurorscg.com

SuperGen, Inc.

CONTACT: Timothy L. Enns of SuperGen, Inc., +1-925-560-0100 x111,tenns@supergen.com; or Sharon Weinstein of Noonan Russo, +1-212-845-4271,sharon.weinstein@eurorscg.com

Back to news